Ejaz Aslam, Semenov Eugene, Spolverato Gaya, Kim Yuhree, Tanner Dylan, Hundt John, Pawlik Timothy M
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Surgery, University of Illinois Hospital and Health Sciences Center, Chicago, IL, USA.
HPB (Oxford). 2014 Dec;16(12):1117-26. doi: 10.1111/hpb.12302. Epub 2014 Jun 26.
The management of patients with colorectal cancer (CRC) and synchronous colorectal liver metastasis (CLM) remains controversial. The present study was conducted in order to assess the clinical and economic impacts of managing synchronous CLM with a staged versus a simultaneous surgery approach.
A total of 224 patients treated for synchronous CLM during 1990-2012 were identified in the Johns Hopkins Hospital liver database. Data on clinicopathological features, perioperative outcomes and total hospital charges (inflation-adjusted) were collected and analysed.
Overall, 113 (50.4%) patients underwent staged surgery and 111 (49.6%) were submitted to a simultaneous CRC and liver operation. At surgery, liver-directed therapy included hepatectomy (75.0%) or combined resection and ablation (25.0%). Perioperative morbidity (30.0%) and mortality (1.3%) did not differ between groups (both P > 0.05). Median total length of hospitalization was longer in the staged (13 days) than the simultaneous (7 days) surgery group (P < 0.001). Median total hospital charges were higher among patients undergoing staged surgery (US$61,938) than among those undergoing a simultaneous operation (US$34,114) (P < 0.01). Median (simultaneous, 32.4 months versus staged, 39.6 months; P = 0.65) and 5-year (simultaneous, 27% versus staged, 29%; P = 0.60) overall survival were similar between groups.
Patients with synchronous CLM managed with either simultaneous or staged surgery have comparable perioperative and longterm outcomes. However, patients treated with simultaneous surgery spent an average of 6 days fewer in hospital, resulting in a reduction of median hospital charges of US$27,824 (55.1%). When appropriate and technically feasible, the simultaneous surgery approach to synchronous CLM should be preferred.
结直肠癌(CRC)合并同时性结直肠肝转移(CLM)患者的治疗仍存在争议。本研究旨在评估分期手术与同期手术治疗同时性CLM的临床和经济影响。
在约翰霍普金斯医院肝脏数据库中识别出1990年至2012年期间接受治疗的224例同时性CLM患者。收集并分析临床病理特征、围手术期结果和总住院费用(经通胀调整)的数据。
总体而言,113例(50.4%)患者接受了分期手术,111例(49.6%)接受了同期结直肠癌和肝脏手术。手术时,肝脏定向治疗包括肝切除术(75.0%)或联合切除与消融术(25.0%)。两组围手术期发病率(30.0%)和死亡率(1.3%)无差异(P均>0.05)。分期手术组的中位总住院时间(13天)长于同期手术组(7天)(P<0.001)。分期手术患者的中位总住院费用(61,938美元)高于同期手术患者(34,114美元)(P<0.01)。两组的中位总生存期(同期为32.4个月,分期为39.6个月;P=0.65)和5年总生存率(同期为27%,分期为29%;P=0.60)相似。
同时性CLM患者接受同期或分期手术治疗的围手术期和长期结果相当。然而,同期手术治疗的患者平均住院时间少6天,导致中位住院费用减少27,824美元(55.1%)。在合适且技术可行的情况下,应优先选择同期手术治疗同时性CLM。